UNLABELLED: The objective of this study was to evaluate the clinical value of combination of diagnostic computed tomography (CT) and somatostatin receptor imaging with (99m)Tc-octreotide acetate SPECT/CT in differentiation of benign pulmonary nodules from cancers. METHODS: This was a retrospective study, 29 patients with suspected pulmonary neoplasm underwent diagnostic CT and (99m)Tc-octreotide SPECT/CT scans, and the tumor-to-normal tissue tracer value (T/N) for (99m)Tc-octreotide was measured. Diagnosis was confirmed by histological analysis. RESULTS: Eighteen of the 29 patients included in this study had lung cancer: 2 with small cell lung cancer and 16 with nonsmall cell lung cancer. The other 11 patients had benign lung lesions: 5 with tuberculosis, 4 with nontuberculosis infection, 1 with hematoma, and 1 with fibroma. (99m)Tc-octreotide uptake (expressed as mean T/N±SD) was significantly higher in lung cancers (2.58±0.91) than benign lesions (1.38±0.79) (p=0.002). Specificity for pulmonary malignant nodule diagnosis was 63.6% for diagnostic CT, 72.7% for somatostatin receptor SPECT/CT imaging, and 81.8% for the combined use of diagnostic CT and somatostatin receptor SPECT/CT imaging. CONCLUSION: Somatostatin receptor imaging with (99m)Tc-octreotide SPECT/CT is useful for the differentiation of benign pulmonary nodules from lung cancers, the combination of diagnostic CT and (99m)Tc-octreotide SPECT/CT further increases the specificity of malignant pulmonary nodule detection.
UNLABELLED: The objective of this study was to evaluate the clinical value of combination of diagnostic computed tomography (CT) and somatostatin receptor imaging with (99m)Tc-octreotide acetate SPECT/CT in differentiation of benign pulmonary nodules from cancers. METHODS: This was a retrospective study, 29 patients with suspected pulmonary neoplasm underwent diagnostic CT and (99m)Tc-octreotide SPECT/CT scans, and the tumor-to-normal tissue tracer value (T/N) for (99m)Tc-octreotide was measured. Diagnosis was confirmed by histological analysis. RESULTS: Eighteen of the 29 patients included in this study had lung cancer: 2 with small cell lung cancer and 16 with nonsmall cell lung cancer. The other 11 patients had benign lung lesions: 5 with tuberculosis, 4 with nontuberculosis infection, 1 with hematoma, and 1 with fibroma. (99m)Tc-octreotide uptake (expressed as mean T/N±SD) was significantly higher in lung cancers (2.58±0.91) than benign lesions (1.38±0.79) (p=0.002). Specificity for pulmonary malignant nodule diagnosis was 63.6% for diagnostic CT, 72.7% for somatostatin receptor SPECT/CT imaging, and 81.8% for the combined use of diagnostic CT and somatostatin receptor SPECT/CT imaging. CONCLUSION: Somatostatin receptor imaging with (99m)Tc-octreotide SPECT/CT is useful for the differentiation of benign pulmonary nodules from lung cancers, the combination of diagnostic CT and (99m)Tc-octreotide SPECT/CT further increases the specificity of malignant pulmonary nodule detection.
Authors: Tao Huang; A Cahid Civelek; Junling Li; Huijie Jiang; Chin K Ng; Gregory C Postel; Baozhong Shen; Xiao-Feng Li Journal: J Nucl Med Date: 2012-06-19 Impact factor: 10.057
Authors: R M Pieterman; J W van Putten; J J Meuzelaar; E L Mooyaart; W Vaalburg; G H Koëter; V Fidler; J Pruim; H J Groen Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: Harm van Tinteren; Otto S Hoekstra; Egbert F Smit; Jan H A M van den Bergh; Ad J M Schreurs; Roland A L M Stallaert; Piet C M van Velthoven; Emile F I Comans; Fred W Diepenhorst; Paul Verboom; Johan C van Mourik; Pieter E Postmus; Maarten Boers; Gerrit J J Teule Journal: Lancet Date: 2002-04-20 Impact factor: 79.321
Authors: Jeffrey L Port; Michael S Kent; Robert J Korst; Roger Keresztes; Matthew A Levin; Nasser K Altorki Journal: Ann Thorac Surg Date: 2004-01 Impact factor: 4.330
Authors: Gerarda J Herder; Richard P Golding; Otto S Hoekstra; Emile F Comans; Gerrit J Teule; Pieter E Postmus; Egbert F Smit Journal: Eur J Nucl Med Mol Imaging Date: 2004-06-03 Impact factor: 9.236